GSK · Pharma and healthcare · one day
GSK (GSK): news on Tuesday 10 November 2026
News from the 24 hours to Tuesday morning, 10 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage focused on positive cancer and HIV trial data, pipeline updates at the Guggenheim conference and growth in Specialty Medicines. The share price edged higher, and the tone was broadly favourable with little negative news.
What drove it
- cancer and HIV trial data
- Guggenheim conference pipeline
- Specialty Medicines growth
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Wed 4 Nov | +5.0 | 14 |
| Thu 5 Nov | +5.0 | 11 |
| Fri 6 Nov | +4.5 | 8 |
| Sat 7 Nov | +4.5 | 17 |
| Sun 8 Nov | +5.7 | 2 |
| Mon 9 Nov | −3.3 | 3 |
| Tue 10 Nov | +6.3 | 13 |
| Wed 11 Nov | +4.5 | 6 |
| Thu 12 Nov | +4.5 | 12 |
| Fri 13 Nov | +4.2 | 14 |
9 stories · 13 headlines · strongest first
Pharma and healthcare on 10 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK proteomics and trial data commentary +6.93 headlines today · Pieces discuss what GSK's cancer, HIV and proteomics work means for shareholders. | ||
| +9.2 | Positive oncology and HIV trial outcomes viewed as beneficial for investors. | |
| +6.7 | Neutral: attention on GSK over fresh oncology results and proteomics. | |
| +5.0 | Proteomics work could sharpen precision medicine targeting, speculative benefit. | |
| GSK has two investor conferences coming up +2.73 headlines today · 7 in all, since 9 November · GSK presents at the Guggenheim healthcare conference, emphasising long-acting biologics and pipeline focus. | ||
| +6.7 | Growth led by Specialty Medicines ahead of investor events. | |
| +5.0 | Conference presentation highlighting long-acting biologics strategy. | |
| +5.0 | Pipeline emphasis presented at investor healthcare conference. | |
| ViiV presents HIV long-acting data at HIV Glasgow +8.31 headline today · ViiV Healthcare presented real-world adherence data and portfolio information at HIV Glasgow. | ||
| +8.3 | Real-world data favours ViiV's long-acting HIV treatment over daily pills. | |
| GSK late-stage COPD and respiratory studies +6.71 headline today · Reports say GSK is stepping up late-stage studies aimed at COPD, along with long-acting respiratory therapies. | ||
| +6.7 | Faster late-stage programmes in respiratory and long-acting treatments. | |
| GSK and Viola Davis shingles education campaign +4.21 headline today · GSK is working with Viola Davis on shingles education. | ||
| +4.2 | Shingles awareness campaign with celebrity involvement supports vaccine brand. | |
| GSK research on disease differences +2.51 headline today · A piece describes GSK's interest in whether the same diagnosis can be a different disease. | ||
| +2.5 | Research interest in disease classification, modest and exploratory. | |
| GSK share price on 9 November +2.51 headline today · GSK shares were quoted at 1,904.5p. | ||
| +2.5 | Small daily share price gain, purely factual market update. | |
| Should you buy GSK shares? +1.71 headline today · The Times asks whether GSK shares are worth buying. | ||
| +1.7 | Investment commentary piece, balanced and non-committal. | |
| GSK survey on respiratory virus disruption +1.51 headline today · 2 in all, since 7 November · A GSK survey found that 79 per cent of respondents worry that viruses could make their chronic conditions worse. | ||
| +1.7 | Company survey on viral health fears, mild awareness content. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.